• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项全国性研究,调查伊布替尼时代前慢性淋巴细胞白血病患者的住院机会性感染。

A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.

机构信息

Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Department of Infectious Diseases, Landspitali University Hospital, Reykjavik, Iceland.

出版信息

Eur J Haematol. 2021 Mar;106(3):346-353. doi: 10.1111/ejh.13553. Epub 2020 Dec 3.

DOI:10.1111/ejh.13553
PMID:33211356
Abstract

OBJECTIVE

Opportunistic infections in chronic lymphocytic leukemia (CLL) have been described in clinical trials, single-center studies, and case reports. We performed a nationwide study to estimate the incidence and impact of inpatient opportunistic infections.

METHODS

The incidence rate (IR) and incidence rate ratio (IRR) for Swedish CLL patients diagnosed 1994-2013, and matched controls were calculated, as well as the case-fatality ratio (CFR).

RESULTS

Among 8989 CLL patients, a total of 829 opportunistic infections were registered (IR 16.6 per 1000 person-years) compared with 252 opportunistic infections in 34 283 matched controls (IR 0.99). The highest incidence in the CLL cohort was for Pneumocystis pneumonia (200 infections, IR 4.03); Herpes zoster (146 infections, IR 2.94), and Pseudomonas (83 infections, IR 1.66) infections. The highest risk relative to matched controls was observed for Pneumocystis pneumonia (IRR 114, 95% confidence interval 58.7-252). The 60-day CFR for CLL patients with opportunistic infections was 23% (188/821), highest for progressive multifocal encephalopathy (5/7, 71%) and aspergillosis (25/60, 42%).

CONCLUSION

We have uniquely depicted the incidence of rare and serious infections in CLL patients and found a relatively high incidence of Pneumocystis pneumonia. Of the most common opportunistic infections, CLL patients with aspergillosis had the poorest prognosis.

摘要

目的

慢性淋巴细胞白血病(CLL)的机会性感染已在临床试验、单中心研究和病例报告中描述。我们进行了一项全国性研究,以估计住院机会性感染的发病率和影响。

方法

计算了 1994-2013 年诊断的瑞典 CLL 患者和匹配对照的发病率(IR)和发病率比(IRR),以及病死率(CFR)。

结果

在 8989 例 CLL 患者中,共登记了 829 例机会性感染(IR 为 16.6/1000 人年),而 34283 例匹配对照中仅登记了 252 例机会性感染(IR 为 0.99)。CLL 队列中发病率最高的是肺囊虫肺炎(200 例感染,IR 为 4.03);带状疱疹(146 例感染,IR 为 2.94)和假单胞菌(83 例感染,IR 为 1.66)感染。与匹配对照相比,肺囊虫肺炎的风险最高(IRR 114,95%置信区间 58.7-252)。发生机会性感染的 CLL 患者的 60 天 CFR 为 23%(188/821),最高的是进行性多灶性白质脑病(5/7,71%)和曲霉病(25/60,42%)。

结论

我们独特地描述了 CLL 患者罕见和严重感染的发病率,并发现肺囊虫肺炎的发病率相对较高。在最常见的机会性感染中,曲霉病的 CLL 患者预后最差。

相似文献

1
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.一项全国性研究,调查伊布替尼时代前慢性淋巴细胞白血病患者的住院机会性感染。
Eur J Haematol. 2021 Mar;106(3):346-353. doi: 10.1111/ejh.13553. Epub 2020 Dec 3.
2
A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival.一项基于人群的研究,旨在探讨慢性淋巴细胞白血病患者严重住院细菌性感染及其对生存的影响。
Eur J Haematol. 2020 Nov;105(5):547-554. doi: 10.1111/ejh.13477. Epub 2020 Jul 13.
3
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.在伊布替尼时代之前,慢性淋巴细胞白血病的生存、死亡原因和合并症的预后作用:一项基于人群的研究。
Eur J Haematol. 2022 Feb;108(2):145-153. doi: 10.1111/ejh.13720. Epub 2021 Nov 11.
4
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.205 例慢性淋巴细胞白血病患者接受伊布替尼治疗的真实世界结果。
Eur J Haematol. 2020 Nov;105(5):646-654. doi: 10.1111/ejh.13499. Epub 2020 Aug 26.
5
Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.退伍军人医疗管理局内接受伊布替尼治疗的慢性淋巴细胞白血病患者侵袭性真菌感染的发生率。
J Oncol Pharm Pract. 2024 Jun;30(4):673-677. doi: 10.1177/10781552231181113. Epub 2023 Jun 12.
6
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.乌布利昔单抗联合伊布替尼与伊布替尼单药治疗复发或难治性高危慢性淋巴细胞白血病患者(GENUINE):一项 3 期、多中心、开放标签、随机试验。
Lancet Haematol. 2021 Apr;8(4):e254-e266. doi: 10.1016/S2352-3026(20)30433-6. Epub 2021 Feb 22.
7
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.接受依鲁替尼治疗的真实世界复发/难治性慢性淋巴细胞白血病患者的生存风险评分。一项校园慢性淋巴细胞白血病研究。
Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
8
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后模型:比较性能分析结果
Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.
9
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.伊布替尼作为慢性淋巴细胞白血病的初始治疗:一项系统评价和荟萃分析。
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
10
Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.新型疗法时代慢性淋巴细胞白血病患者感染风险分析
Leuk Lymphoma. 2018 Mar;59(3):625-632. doi: 10.1080/10428194.2017.1347931. Epub 2017 Jul 11.

引用本文的文献

1
Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU/EEA, Switzerland, and the UK.欧盟/欧洲经济区、瑞士和英国疾病风险增加人群中带状疱疹发病率的系统文献综述。
Infect Dis Ther. 2024 May;13(5):1083-1104. doi: 10.1007/s40121-024-00963-w. Epub 2024 Apr 24.
2
Towards personalized prevention of Herpes zoster infection in patients with hematologic diseases or hematopoietic stem cell transplant recipients: a position paper from an <I>ad hoc</I> Italian expert panel.针对血液系统疾病或造血干细胞移植受者中带状疱疹感染的个体化预防:来自意大利专家组的一份立场文件。
Haematologica. 2024 Nov 1;109(11):3496-3504. doi: 10.3324/haematol.2023.284417.
3
Fatal Powassan virus encephalitis in patients with chronic lymphocytic leukemia.
慢性淋巴细胞白血病患者发生的致命性波瓦桑病毒脑炎。
Blood Cancer J. 2022 Oct 7;12(10):143. doi: 10.1038/s41408-022-00737-y.
4
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.BTK 抑制剂可损害 CLL 患者对重组带状疱疹疫苗的体液和细胞应答。
Blood Adv. 2022 Mar 22;6(6):1732-1740. doi: 10.1182/bloodadvances.2021006574.
5
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.实体瘤和血液系统恶性肿瘤患者疱疹病毒再激活的管理:德国血液学和肿瘤医学学会传染病工作组(AGIHO)关于单纯疱疹病毒 1 型、单纯疱疹病毒 2 型和水痘带状疱疹病毒指南的更新。
Ann Hematol. 2022 Mar;101(3):491-511. doi: 10.1007/s00277-021-04746-y. Epub 2022 Jan 7.
6
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies.布鲁顿酪氨酸激酶(BTK)抑制剂依鲁替尼和阿卡替尼在B细胞恶性肿瘤以外的人类疾病中的临床试验。
Front Oncol. 2021 Oct 28;11:737943. doi: 10.3389/fonc.2021.737943. eCollection 2021.
7
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets - Beyond B Lymphocytes.布鲁顿酪氨酸激酶(BTK)抑制剂依鲁替尼和阿卡拉布替尼对不同免疫细胞亚群的多方面免疫调节作用——超越B淋巴细胞。
Front Cell Dev Biol. 2021 Aug 13;9:727531. doi: 10.3389/fcell.2021.727531. eCollection 2021.